X0609 4 2026-05-04 0001438533 Travere Therapeutics, Inc. TVTX 0001283303 REED ELIZABETH E false C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 false true false false Chief Legal Officer and GC 1 Common Stock 2026-05-04 4 M 0 20000 17.96 A 125211 D Common Stock 2026-05-04 4 S 0 20000 45 D 105211 D Common Stock 2026-05-04 4 M 0 4250 0 A 109461 D Common Stock 2026-05-05 4 S 0 2174 46.65 D 107287 D Common Stock 2026-05-06 4 S 0 2076 43.95 D 105211 D Employee stock option (right to buy) 17.96 2026-05-04 4 M 0 20000 0 D 2029-05-09 Common Stock 20000 0 D Performance-based restricted stock units 2026-05-04 4 A 0 8500 0 A Common Stock 8500 8500 D Performance-based restricted stock units 2026-05-04 4 M 0 4250 0 D Common Stock 4250 4250 D This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. The stock option is fully vested and exercisable. Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. /s/ Elizabeth E. Reed 2026-05-06